Robert Schilz, DO
Critical Care Medicine · Cleveland, OHNPI 1972523538
Payments from drug & device makers
Across 645 payments — averaging $1205.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$280K
- Merck$150K
- Actelion Pharmaceuticals US, Inc.$137K
- Roche Products Limited$137K
- Bayer$36K
- Baxter Healthcare$35K
- plus $2K from 36 others
What the payments were for
- Consulting fees$37,70911%
- Speaking & faculty fees$279,42379%
- Travel & lodging$25,2677%
- Food & beverage$13,3124%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$119,281
- OPSUMIT$119,144
- Adempas$35,732
- WINREVAIR$33,665
- TYVASO$26,015
- REMODULIN$21,898
- ORENITRAM$3,941
- FLOWTRIEVER CATHETER, S$167
- CT THROMBECTOMY SYSTEM KIT$167
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$109
- BOSENTAN$102
How this compares
$777,555 in reported general payments places this provider in the 95th percentile of 285 critical care medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 156 | $3,426,800 |
| Tyvaso DpiTreprostinil | 141 | $3,377,436 |
| OpsumitMacitentan | 263 | $3,352,336 |
| Orenitram ErTreprostinil Diolamine | 162 | $1,323,477 |
| AdempasRiociguat | 81 | $1,114,474 |
| Ambrisentan | 222 | $673,103 |
| Tadalafil | 452 | $307,906 |
| LetairisAmbrisentan | 24 | $306,437 |
| WinrevairSotatercept-Csrk | 16 | $223,661 |
| TracleerBosentan | 12 | $147,496 |
| OpsynviMacitentan/Tadalafil | 11 | $142,137 |
| RemodulinTreprostinil Sodium | 12 | $58,801 |
| Sildenafil Citrate | 90 | $15,564 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $9,871 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Tracleer, Opsynvi | $137,477 | $7,068,768442 claims |
| BayerAdempas | $36,210 | $1,114,47481 claims |
| GileadLetairis | $44 | $306,43724 claims |
| MerckWinrevair | $149,784 | $223,66116 claims |
| United Therapeutics CorporationRemodulin | $280,286 | $58,80112 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $255 | $15,11823 claims |
| GSKBreo Ellipta | $63 | $4,16412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 285 critical care medicine providers in Ohio.
Other critical care medicine in Cleveland
- Neal ChaissonCleveland$450K
- Rafid FadulCleveland$31K
- Chiedozie UdehCleveland$24K
- Roshni SreedharanCleveland$23K
- Negmeldeen MamounCleveland$17K
- Kingman StrohlCleveland$13K
- Arvind SugunessCleveland$5K
- Maeve MacmurdoCleveland$4K
- Eric HarvesterCleveland$4K
- Angela JohnsonCleveland$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.